The rationale for new therapies in acute ischaemic stroke

Journal of Clinical Pharmacy and Therapeutics

Volumn 21, Issue 6, 1996, Pages 377-391

  Dyker, A G ^a   Lees, K R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; AMINO ACID RECEPTOR STIMULATING AGENT; APTIGANEL; DIZOCILPINE; EXCITATORY AMINO ACID; FIBRINOLYTIC AGENT; FREE RADICAL; GLUTAMIC ACID; LUBELUZOLE; METABOTROPIC RECEPTOR; NIMODIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; STREPTOKINASE;

ARTICLE; BLOOD CLOT LYSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; STROKE;

EID: 0030435854     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1996.tb00036.x     Document Type: Article

References (105)

1. Secretary of State for Health. (1992) The Health of the Nation. HMSO, London.
2. Office of Population Censuses and Surveys. (1992) Review of the Registrar General on Deaths by Cause, Sex and Age in England and Wales. Series DH2, No. 19. OPCS, London.
3. Lindley RI, Amayo EO, Marshall J, Sandercock PAG, Dennis M, Warlow CP. (1995) Acute stroke treatment in UK hospitals: the Stroke Association survey of consultant opinion. Journal of the Royal College of Physicians of London, 29, 479-484.
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. (1995) Tissue plasminogen activator for acute ischemic stroke. The New England Journal of Medicine, 333, 1581-1587.
5. Renkawek K, Lazarewicz JW. (1989) Protective effect of the calcium entry blocker nimodipine on cerebellar organotypic cultures submitted to anoxia. Neuropatologia Polska, 27, 323-329.
6. Freese A, DiFiglia M, Koroshetz WJ, Flint Beal M, Martin JB. (1990) Characterisation and mechanism of glutamate neurotoxicity in primary striatal cultures. Brain Research, 521, 254-264.
7. Pauwels PJ, Van Assouw HP, Peters L, Moeremans M, Leysen JE. (1992) Chronic treatment with sabeluzole protects cultured rat brain neurons from the neurotoxic effects of excitatory amino acids. Synapse, 12, 271-290.
8. McCulloch J. (1992) Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. British Journal of Clinical Pharmacology, 34, 106-114.
9. Muir KW, Lees KR. (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke, 26, 503-513.
10. Heiss WD. (1983) Flow thresholds of functional and morphological damage of brain tissue. Stroke, 14, 329-331.
11. Pulsinelli W. (1992) Pathophysiology of acute ischaemic stroke. Lancet, 339, 533-536.
12. Astrup J, Symon L, Branston NM, et al. (1976) Cortical neuronal function during ischaemia. Archives of Neurology, 33, 813-820.
13. Branston NM, Strong AJ, Symon L. (1977) Extracellular potassium activity, evoked potential and tissue blood flow: Relationship during progressive ischaemia in baboon cerebral cortex. Journal of the Neurological Sciences, 32, 305-321.
14. Heiss WD, Fink GR, Pietrzyk U, Huber M, Herholz K. (1992) Do PET data support a therapeutic window in ischemic stroke? In: Pharmacology of Cerebral Ischemia. eds Krieglstein J, Oberpichler-Schwenk H, pp. 529-534, Wissenschaftliche Verlagsgesellschaft, Stuttgart.
15. Heiss WD, Graf R. (1994) The ischemic penumbra. Current Opinion in Neurology, 7, 11-19.
16. Astrup J, Siesjö BK, Symon L. (1981) Thresholds in cerebral ischemia - the ischemic penumbra. Stroke, 12, 723-725.
17. Kaplan B, Brint S, Tanabe J, Jacewicz M, Wang X, Pulsinelli W. (1991) Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia. Stroke, 22, 1032-1039.
18. Pappata S, Fiorelli M, Romel T, et al. (1993) PET study of changes in local brain hemodynamics and oxygen metabolism after unilateral middle cerebral artery occlusion in baboons. Journal of Cerebral Blood flow and Metabolism, 13, 416-424.
19. Heiss WD, Huber M, Fink GR, Herholz K, Pietrzyk U, Wagner R, Wienhard K. (1992) Progressive derangement of peri-infarct viable tissue in ischemic stroke. Journal of Cerebral Blood Flow and Metabolism, 12, 193-203.
20. Gruppo Italiano per lo studio della streptochinasi nell infarto miocadico. (1987) Long-term effects of intravenous thrombolysis in acute myocardial infarction. Final report of the GISSI study. Lancet, 2, 871-874.
21. The GUSTO investigators. (1993) The effects of tissue plasminogen activator, streptokinase or both, on coronary artery patency ventricular function and survival after acute myocardial infarction. New England Journal of Medicine, 329, 1615-1627.
22. Marchal G, Serrati C, Rioux P, et al. (1993) PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet, 341, 925-927.
23. Donnan GA, Davis SM, Chambers R, et al. (1995) Trials of streptokinase in severe acute ischaemic stroke. Lancet, 345, 378-379.
24. The Multicenter Acute Stroke Trial - Europe Study Group. (1996) Thrombolytic therapy with streptokinase in acute ischemic stroke. The New England Journal of Medicine, 335, 145-150.
25. Sandercock P. (1995) Thrombolytic therapy for acute ischaemic stroke: promising, perilous or unproven? Lancet, 346, 1504.
26. Candelise L, Aritzu E, Ciccone A, Ricci S, Wardlaw J. (1995) Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet, 346, 1509-1514.
27. The European Cooperative Acute Stroke Study (ECASS). (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. Journal of the American Medical Association, 274, 1017-1025.
28. Ueda T, Hatakeyama T, Kumon Y, Sakaki S, Uraoka T. (1994) Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in actue ischemic stroke by initial SPECT. Stroke, 25, 298-303.
29. Lipton SA, Rosenberg PA. (1994) Excitatory amino acids as a final common pathway for neurologic disorders. The New England Journal of Medicine, 330, 613-622.
30. Bouvier M, Szatkowski M, Amato A, Attwell D. (1992) The glial cell glutamate uptake carrier countertransports pH-changing anions. Nature, 360, 471-474.
31. Storck T, Schulte S, Hofmann K, Stoffel W. (1992) Structure, expression, and functional analysis of a Na+ -dependent glutamate/aspartate transporter from rat brain. Proceedings of the National Academy of Sciences USA, 89, 10955-10959.
32. Pines G, Danbolt NC, Bjorås M, et al. (1992) Cloning and expression of a rat brain L-glutamate transporter. Nature, 360, 464-467.
33. Kanai Y, Hediger MA. (1992) Primary structure and functional characterization of a high affinity glutmsate transporter. Nature, 360, 467-471.
34. Bliss TVP, Collingridge GL. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361, 31-39.
35. Shimada N, Graf R, Rosner G, Wakayama A, George CP, Heiss WD. (1989) Ischemic flow threshold for extracellular glutamate increase in cat cortex. Journal of Cerebral Blood Flow and Metabolism, 9, 603-606.
36. Jones TJ, Morawetz RB, Crowell RM, Marcoux FW, Fitzgibbon SJ, Degirolami U, Ojemann RG. (1981) Thresholds of focal cerebral ischemia in awake monkeys. Journal of Neurosurgery, 54, 773-782.
37. Perry DC, Wei H, Rosenthal RE, et al. (1994) Autoradiographic analysis of L- and N-type voltage-dependent calcium channel binding in canine brain after global cerebral ischemia/reperfusion. Brain Research, 638, 95-102.
38. Uematsu D, Greenberg JH, Hickey WF, Reivich M. (1989) Nimodipine attenuates both increase in cytosolic free calcium and histologic damage following focal cerebral ischaemia and reperfusion in cats. Stroke, 20, 1531-1537.
39. Hakim AM, Evans AC, Berger H, et al. (1989) The effect of Nimodipine on the evolution of human cerebral infarction studied by PET. Journal of Cerebral Blood Flow and Metabolism, 9, 523-534.
40. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T. (1994) Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovascular Diseases, 4, 204-210.
41. Zornow MH, Prough DS. (1996) Neuroprotective properties of calcium-channel blockers. New Horizons, 4, 107-114.
42. Miljanich GP, Ramachandran J. (1995) Antagonists of neuronal calcium channels: structure, function and therapeutic implications. Annual Review of Pharmacology and Toxicology, 35, 707-734.
43. Siesjö BK. (1992) Pathophysiology and treatment of focal cerebral ischemia. Part II. Mechanisms of damage and treatment. Journal of Neurosurgery, 77, 337-354.
44. Verrecchia C, Boulu RG, Plotkine M. (1995) Neuroprotective and deleterious effects of nitric oxide on focal cerebral ischemia-induced neurone death. Advances in Neuroimmunology, 5, 359-378.
45. Ignarro LJ. (1991) Signal transduction mechanisms involving nitric oxide. Biochemical Pharmacology, 41, 485-490.
46. Knowles RG, Palacios M, Palmer RMJ, Moncada S. (1989) Formation of nitric oxide from L-argine in the central nervous system: A transduction mechanism for stimulation of the soluble guanylate cyclase. Proceedings of the National Academy of Science USA, 86, 5159-5162.
47. Schmidt HHHW, Lohman SM, Walter U. (1993) The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochemical and Biophysical Acta, 1178, 153-175.
48. Faraci FM. (1991) Role of endothelium-derived relaxing factor in cerebral circulation: large arteries vs. microcirculation. American Journal of Physiology, 261, 1038-1042.
49. Wei EP, Kukreja R, Kontos HA. (1992) Effects of inhibition of nitric oxide synthesis on cerebral vasodilation and endothelium-derived relaxing factor from acetylcholine. Stroke, 23, 1623-1629.
50. Bauknight GC, Faraci FM, Heistad DD. (1992) Endothelium-derived relaxing factor modulates noradrenergic constriction of cerebral arterioles in rabbits. Stroke, 23, 1522-1526.
51. Rosenblum WI, Nishimura H, Nelson GH. (1990) Endothelium dependent L-arg- and L-NMMA-sensitive mechanisms regulate tone of brain microvessels. American Journal of Physiology, 259, 1396-1401.
52. Mocada S, Palmer RMJ, Higgs EA. (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacological Reviews, 43, 109-142.
53. Marletta MA. (1993) Nitric oxide synthase structure and mechanism. Journal of Biological Chemistry, 268, 12231-12234.
54. Mayhan WG. (1990) Impairment of endothelium-dependent dilatation of basilar artery during chronic hypertension. American Journal of Physiology, 259, 1455-1462.
55. 2 in responses of cerebral arterioles during chronic hypertension. American Journal of Physiology, 262, 539-543.
56. Mayhan WG, Faraci FM, Heistad DD. (1987) Impairment of endothelium-dependent responses of cerebral arterioles in chronic hypertension. American Journal of Physiology, 253, 1435-1440.
57. Mayhan WG, Faraci FM, Heistad DD. (1988) Responses of cerebral arterioles to adenosine 5′-diphosphate, serotonin and the thromboxane analogue U-46619 during chronic hypertension. Hypertension, 12, 556-561.
58. Fujii K, Heistad DD, Faraci FM. (1992) Effect of diabetes mellitus on flow-mediated and endothelium-dependent dilatation of the basilar artery. Stroke, 23, 1494-1498.
59. Mayhan WG. (1989) Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. American Journal of Physiology, 256, 621-625.
60. Mayhan WG, Simmons LK, Sharpe GM. (1991) Mechanisms of impaired responses of cerebral arterioles during diabetes mellitus. American Journal of Physiology, 260, 319-326.
61. Garthwaite J, Charles SL, Chess-Williams R. (1988) Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature, 336, 385-388.
62. Garthwaite J, Southam E, Anderson MA. (1989) A kainate receptor linked to NO synthesis from arginine. Neurochemistry, 53, 1952-1954.
63. Ambrosini A, Racagni G. (1993) Glutamate receptor-induced cyclic GMP formation in primary cultures of mesencephalic neurons. Biochemical and Biophysical Research Communications, 193, 1098-1103.
64. Marin P, Quignard JF, Lafon-Cazal M, Bockaert J. (1993) Non-classical glutamate receptors, blocked by both NMDA and non-NMDA antagonists, stimulate nitric ozide production in neurons. Neuro-pharmacology, 32, 29-36.
65. Okada D. (1992) Two pathways of cyclic GMP production through glutamate receptor-mediated nitric oxide synthesis. Journal of Neurochemistry, 59, 1203-1210.
66. Malinski T, Bailey F, Zhang ZG, Chopp M. (1993) Nitric oxide measured by a prophyrinic microsensor in rat brain after transient middle cerebral artery occlusion. Journal of Cerebral Blood Flow and Metabolism, 13, 355-358.
67. Nishimura H, Rosenblum WI, Nelson GH, Boynton S. (1991) Agents that modify EDRF formation alter antiplatelet properties of brain arteriolar endothelium in vivo. American Journal of Physiology, 261, 15-21.
68. Lipton SA, Chol Y-B, Pan Z-H, et al. (1993) A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature, 364, 626-632.
69. Lees G, Anzal M. (1996) Stroke and cerebral ischaemia: Perspectives for clinical treatment and new drugs based on molecular pathophysiology. Pharmaceutical Journal, 256, 269-275.
70. Foster AC, Fagg GE. (1987) Taking apart the NMDA receptor. Nature, 329, 395-396.
71. Olney JW, Labruyere J, Price MT. (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 244, 1360-1362.
72. Fix AS, Horn JW, Wightman KA, et al. (1993) Neuronal vacuolization and necrosis induced by the non-competitive N-methyly D-aspartate (NMDA) antagonist MK (+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Experimental Neurology, 123, 204-215.
73. Palmer GC, Clark B, Hutchison JB. (1993) Antiepieleptic and neuroprotective potential of remacemide hydrochloride. Drugs of the Future, 18, 1021-1042.
74. Allen HL, Iversen LL. (1990) Phencyclidine, dizocilpine, and cerebrocortical neurons. Science, 247, 221.
75. Albers GW, Atkinson R, Kelley R, Rosenbaum DM. (1994) Safety, tolerability, and pharmacokinetics of the N-methyl D-aspartate antagonist dextrorphan in patients with an acute stroke. Neurology, 44 (Suppl. 2), 270-271.
76. Muir KW, Grosset DG, Gamzu E, Lees KR. (1994) Pharmacological effects of the non-competitive NMDA antagonist CNS1102 in normal volunteers. British Journal of Clinical Pharmacology, 38, 33-38.
77. Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J. (1996) The effects of Lifarizine in acute cerebral infarction: A pilot safety study. Cerebrovascular Diseases, 6, 156-160.
78. Muir KW, Lees KR, Hamilton SJ, George CF. (1996) Tolerability and Safety of 619C89 in Acute Stroke. Proceedings of the 20th International Joint Conference on Stroke and Cerebral Circulation, p. 157.
79. Scatton B. (1994) Eliprodil. Proceedings of the 5th International Symposium on Pharmacology of Cerebral Ischemia, Marburn, Germany.
80. McDonald JW, Silverstein FS, Johnston MV. (1990) Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats. Neuroscience Letters, 109, 234-238.
81. Collins R, Peto R, Flather M, et al. (1995) ISIS 4. A randomised factorial trial assessing oral captopril, oral mononitrate, and i.v. magnesium sulphate in 58 050 patients with suspected myocardial infarction. Lancet, 345, 669-685.
82. Muir KW, Lees KR. (1995) A randomised, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke, 26, 1183-1188.
83. Bucan AM, Lesiuk H, Barnes KA, Li H, Huang ZG, Smith KE, Xue D. (1993) AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke, 24 (Suppl. 12), 148-152.
84. Sheardown MJ, Neilsen E, Hansen AJ, Jacobsen P, Honore T. (1990) 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F)quinoxaline: a neuroprotectant for cerebral ischemia. Science, 247, 571-574.
85. McManigle JE, Taviera DaSilva AM, Dretchen KL, Gillis RA. (1994) Potentiation of MK-801-induced breathing impairment by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F)quinoxaline. European Journal of Pharmacology, 252, 11-17.
86. Saji M, Reis DJ. (1987) Delayed transneuronal death of substantia nigra neurons prevented by γ-aminobutyric acid. Science, 235, 66-69.
87. Brailowsky S, Knight RT, Blood K, Scabini D. (1986) γ-Aminobutyric acid-induced potentiation of cortical hemiplegia. Brain Research, 362, 322-330.
88. Lyden PD, Lonzo L. (1994) Combination therapy protects ischemic brain in rats. Stroke, 25, 189-196.
89. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J. (1996) Lubeluzole in acute ischemic stroke: A double-blind, placebo-controlled phase II trial. Stroke, 27, 76-81.
90. Diener HC, Hacke W, Lees K, Timmerhuis T, Haan J, Hantson L, Hennerici M. (1996) Cardiovascular safety of lubeluzole in patients with acute ischaemic stroke. Cerebrovascular Diseases, 6 (Suppl. 2), 77.
91. Schmidley JW. (1990) Free radicals in central nervous system ischemia. Stroke, 21, 1086-1090.
92. Randomised trial of tirilizad in acute stroke (RANTTAS) by the RANTTAS investigators, the neuroclinical trials centre, University of Virginia, Charlottesville, VA and the North American RANTTAS participants. (1996) Stroke, 27 (Abstract), 195.
93. Halliwell B, Gutteridge JMC. (1985) Oxygen radicals and the nervous system. Trends in Neurosciences, 8, 22-26.
94. He YY, Hsu CY, Erzin AM, Miller MS. (1993) Polyethylene glycol-conjugated superoxide dismutase in focal cerebral ischemia-reperfusion. American Journal of Physiology, 265, 34-41.
95. del Zoppo GJ, Schmid-Schönbein GW, Mori E, et al. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke, 22, 1276-1283.
96. Chen H, Chopp M, Bodzin G. (1992) Neutropenia reduces the volume of cerebral infarct after transient middle cerebral artery occlusion in the rat. Neuroscience Research Communications, 11, 93-99.
97. Dutka AJ, Kochanek PM, Hallenbeck JM. (1989) Influence of granulocytopenia on canine cerebral ischemia induced by air embolism. Stroke, 20, 390-395.
98. Matsu Y, Onodera H, Shiga Y, et al. (1994) Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effect of neutrophil depletion. Stroke, 25, 1469-1475.
99. Clark WM, Madden KP, Rothlein R, Zivin JA. (1991) Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke, 22, 877-883
100. Chen H, Chopp M, Zhang R, et al. (1994) Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Annals of Neurology, 35, 447-452.
101. Chopp M, Shang RI, Chen H, et al. (1994) Post ischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Stroke, 25, 869-876.
102. Jiang N, Zhang RL, Chen H, Chopp M. (1994) Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient (2 h) but not after permanent MCA occlusion in the rat. Neuroscience Research Communications, 15, 85-94.
103. Bowes MP, Zivin JA, Rothlein R. (1993) Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Experimental Neurology, 119, 215-219.
104. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury by monoclonal antibody to intercelluar adhesion molecule. Journal of Neurosurgery, 75, 623-627.
105. Zhang RL, Chopp M, Li Y, et al. (1994) Anti-ICAM-1 antibody reduces ischemic cell damage after transient cell damage after transient middle cerebral artery occlusion in the rat. Neurology, 44, 1747-1751.